A vaccine designed to prevent shingles is quietly rewriting our understanding of biological aging β slowing epigenetic clocks, reducing dementia risk by up to 51%, and protecting the heart for years.
What started as protection against a painful rash has become one of the most promising β and unexpected β anti-aging interventions in modern medicine.
3,884
Adults studied (age 70+) USC/HRS cohort
~20%
Dementia reduction Natural experiments
26%
Lower MACE risk 1.27M South Koreans
4+ yr
Persistent benefit Epigenetic aging
Multi-Domain Anti-Aging Convergence
The Story
From Rash Prevention to Longevity Intervention
Shingrix (recombinant zoster vaccine, GSK) was approved in 2017 to prevent herpes zoster β the painful reactivation of chickenpox virus lurking in nerve ganglia. But since 2024, a cascade of natural experiments across four countries has revealed something far more interesting: the vaccine appears to slow biological aging itself.
The USC Leonard Davis School study (Jan 2026) provided the mechanistic puzzle piece β showing slower epigenetic and transcriptomic aging clocks in vaccinated adults, with effects persisting 4+ years. The working hypothesis: trained immunity β the vaccine epigenetically reprograms innate immune cells, dampening the chronic low-grade inflammation ("inflammaging") that drives age-related disease.
Key Insight
Why This Matters for Longevity
Unlike most anti-aging interventions stuck in preclinical stages, Shingrix is already FDA-approved, widely available, and recommended for adults 50+. The convergence of evidence across three separate domains β epigenetic aging, neurodegeneration, and cardiovascular disease β is unprecedented for a single intervention.
Eric Topol's summary (Jan 2026): "You get protection vs Shingles, slowing of your biological aging (by methylation and RNA metrics), and ~20% reduction of dementia, predominantly related to Alzheimer's disease."
Kim & Crimmins (USC, Jan 2026) measured how shingles vaccination affects 7 independent biological aging domains in 3,884 adults age 70+ from the U.S. Health and Retirement Study.
*Paradox: The neurodegenerative blood biomarkers (p-tau181, GFAP, NfL, AΞ²42/40) showed no significant difference, despite 4 large natural experiments showing clear dementia risk reduction. The anti-dementia effect may operate through inflammation and epigenetic pathways rather than direct amyloid/tau mechanisms.
Domain Effect Sizes (Regression Coefficients)
Epigenetic Clocks Comparison
Temporal Dynamics
How Long Do Benefits Last?
Benefits were most pronounced within the first 3 years post-vaccination, but slower epigenetic and transcriptomic aging persisted beyond 4 years. Inflammation and innate immunity effects became significant only after 4+ years, suggesting different temporal dynamics for different biological pathways.
Four independent natural experiments across three continents β plus additional observational studies β show consistent dementia risk reduction from shingles vaccination.
π΄σ §σ ’σ ·σ ¬σ ³σ Ώ Wales
280,000
~20% reduction in new dementia diagnoses over 7 years. First natural experiment to establish the relationship using birthdate eligibility cutoffs.
Zostavax
Eyting et al. Nature (2025) Β· Geldsetzer Lab, Stanford
π¦πΊ Australia
101,219
Replicated Welsh findings in Australian population with similar birthdate cutoff design. Consistent dementia protection in an independent healthcare system.
Zostavax
Pomirchy et al. JAMA (2024) Β· Geldsetzer Lab, Stanford
πΊπΈ United States
103,615
Compared Shingrix (recombinant) vs. Zostavax (live): Shingrix provided 17% more dementia-free time within 6 years, suggesting adjuvanted formulation is superior.
Shingrix vs Zostavax
Taquet et al. Nature Medicine (2024)
π¨π¦ Canada
464,000+
Largest study. Absolute 2.0 percentage point dementia reduction in Ontario. Triangulated with non-vaccine provinces as control. 5.5 years follow-up.
Two doses of recombinant Shingrix β 51% dementia risk reduction. Comparable across subgroups, remains statistically significant after adjustments.
Shingrix 2-dose
Nature Communications (2025)
π΄σ §σ ’σ ·σ ¬σ ³σ Ώ Wales (Extended)
280,000
Extended Cell (2025) analysis: vaccine not only prevents/delays MCI but also slows disease course in those already with dementia and reduces dementia-attributable deaths.
Zostavax Β· Disease course
Geldsetzer et al. Cell (2025)
Dementia Risk Reduction Across Studies
Sex Differences
Greater Protection in Women
Three of four natural experiments found significantly greater dementia protection in women. This aligns with known sex differences in Alzheimer's prevalence (women carry ~two-thirds of the AD burden) and may relate to sex-specific immune and epigenetic responses to vaccination.
Why "natural experiments" matter: Unlike typical observational studies that compare vaccinated vs. unvaccinated people (prone to "healthy vaccinee" bias β people who get vaccinated tend to be healthier overall), natural experiments exploit birthdate eligibility cutoffs for vaccine programs. People born just before vs. just after the cutoff are nearly identical in all ways except vaccination status, approximating a randomized trial at massive scale.
Cardiovascular Protection
A nationwide South Korean study of 1.27 million adults found shingles vaccination associated with significantly lower risk of major adverse cardiovascular events β lasting up to 8 years.
β26%
Overall MACE (MI, stroke, HF, CV death)
1.27M
Participants Age 50+ (South Korea)
8 yr
Duration of cardiovascular benefit
Study Details
South Korea Nationwide Cohort (European Heart Journal, 2025)
Researchers analyzed data from 1,271,922 adults aged 50+ from 2012 onwards. Using propensity score matching and extensive confounder adjustment, vaccinated individuals showed 26% lower risk of the composite MACE endpoint. The protective effect was especially pronounced in men and those aged 60+.
Proposed Mechanism
Varicella zoster virus (VZV) reactivation β even subclinical β can directly damage blood vessels through viral vasculopathy, trigger inflammatory cascades, and activate coagulation pathways. By preventing VZV reactivation, the vaccine may:
Via trained immunity: broadly dampen inflammaging pathways
Clinical Context
Cardiovascular disease remains the #1 cause of death globally. A 26% MACE reduction from a widely available vaccine is comparable to β or exceeds β many cardiovascular drug interventions:
Shingrix (26%)
Statins (25β35%)
SGLT2i (20β25%)
GLP-1 RA (14β26%)
Trained Immunity: The Mechanism
How does a virus-specific vaccine slow systemic biological aging? The answer lies in trained immunity β a form of innate immune memory that epigenetically reprograms myeloid cells.
Trained Immunity Pathway
What Is Trained Immunity?
Trained immunity is a form of innate immune memory β distinct from classical adaptive immunity (antibodies/T cells). After exposure to certain stimuli (BCG vaccine, Ξ²-glucan, or in this case, Shingrix's AS01B adjuvant), innate immune cells undergo long-lasting epigenetic and metabolic reprogramming:
Histone modifications: H3K4me3 and H3K27ac marks at promoters of immune genes are stably altered
DNA methylation: Global shifts in CpG methylation patterns β directly affecting epigenetic aging clocks
Metabolic shift: Enhanced glycolysis and glutaminolysis in resting monocytes
Progenitor reprogramming: Changes extend to bone marrow hematopoietic stem cells (HSCs), ensuring trained state persists through cell division
The BCG Precedent
The concept was first established with BCG (tuberculosis vaccine), which protects against unrelated infections and reduces all-cause mortality in infants by 30-50%. Shingrix's AS01B adjuvant (MPL, a TLR4 agonist + QS-21 saponin) is a particularly potent inducer of trained immunity β potentially more so than BCG.
Key distinction from adaptive immunity: Trained immunity is nonspecific β it doesn't remember specific pathogens. Instead, it broadly enhances the innate immune system's ability to respond to any threat while simultaneously dampening maladaptive chronic inflammation.
Explore how shingles vaccination might affect biological aging outcomes based on the USC study data. This is an educational model β not medical advice.
Your Profile
Input Parameters
Age72
Baseline Inflammation (CRP mg/L)3.0
Years Since Vaccination2
Chronic Conditions (count)1
Exercise (hours/week)3
Presets
β1.8
Estimated Biological Age Offset (years)
Negative = biologically younger than chronological age
Domain-Specific Impact Estimate
Disclaimer: This calculator provides educational estimates based on published effect sizes from the USC study. Individual results depend on genetics, lifestyle, medical history, and many unmeasured factors. The model uses simplified linear extrapolation of regression coefficients. Consult your healthcare provider about vaccination decisions.
References & Evidence
Primary literature, reviews, and commentary informing this deep dive.
Primary Studies
Kim JK, Crimmins EM. Association between shingles vaccination and slower biological aging: Evidence from a U.S. population-based cohort study. J Gerontol A Biol Sci Med Sci. 2026;81(3):glag008. doi:10.1093/gerona/glag008
Eyting M, Xie M, Geldsetzer P, et al. A natural experiment on the effect of herpes zoster vaccination on dementia. Nature. 2025. doi:10.1038/s41586-025-08800-x
Taquet M, Dercon Q, Harrison PJ. Shingrix vs Zostavax and dementia risk. Nature Medicine. 2024;30:2571β2579. doi:10.1038/s41591-024-03201-5
Pomirchy IV, et al. Herpes zoster vaccination and dementia in Australian adults. JAMA. 2024. JAMA
Geldsetzer P, et al. Shingles vaccination and dementia in Canada: a natural experiment. Lancet Neurology. 2026. Lancet Neurol
Geldsetzer P, et al. The effect of shingles vaccination at different stages of the dementia disease course. Cell. 2025;184(24). doi:10.1016/j.cell.2025.11.019
Recombinant zoster vaccine associated with 51% reduced dementia risk in adults β₯65 years. Nature Communications. 2025. doi:10.1038/s41467-026-69289-0
Live zoster vaccination and cardiovascular outcomes: a nationwide South Korean study. European Heart Journal. 2025;46(30):2991. doi:10.1093/eurheartj/ehae123
Netea MG, et al. Trained immunity: a program of innate immune memory in health and disease. Science. 2016;352(6284):aaf1098. doi:10.1126/science.aaf1098
Shingles vaccination and neuroimmune vulnerability. Trends in Neurosciences. 2025. ScienceDirect
Epigenetic adjuvants: durable reprogramming of the innate immune system with adjuvants. Trends in Immunology. 2022. doi:10.1016/j.it.2022.02.006
Epigenetic reprogramming mediates monocyte and heterologous T cell-derived cytokine responses after BCG vaccination. medRxiv. 2024. doi:10.1101/2024.03.27.24304976
Commentary & Reviews
Topol E. Spotlight on the Shingles VaccineβAgain! Ground Truths (Substack). Jan 22, 2026. Ground Truths
Link between shingles vaccine and slowed dementia is 'promising.' Harvard T.H. Chan School of Public Health. 2025. Harvard
Shingles vaccine may slow biological aging and reduce inflammation. ScienceDaily. Feb 25, 2026. ScienceDaily
For those living with dementia, new study suggests shingles vaccine could slow the disease. Stanford Medicine. Dec 2, 2025. Stanford Medicine
Shingles Vaccine Lowers Risk of Dementia, Major Cardiovascular Events. IDSA. 2025. IDSA
Study Design & Methodology
Levine ME, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging. 2018;10(4):573β591. [PhenoAge clock]
Lu AT, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging. 2019;11(2):303β327. [GrimAge clock]
Belsky DW, et al. DundedinPACE, a DNA methylation biomarker of the pace of aging. eLife. 2022;11:e73420. [DundedinPACE clock]
Health and Retirement Study (HRS). University of Michigan. hrs.isr.umich.edu [NIA U01AG009740]
Shingrix Anti-Aging Deep Dive Β· Built by Q Β· Data from USC Leonard Davis, Nature, Nature Medicine, Cell, Lancet Neurology, European Heart Journal Β· Not medical advice